GET DAILY SIGNALSNovo Nordisk (NVO) Q3 Beat: Sales Top Estimates, Guidance Raised, Shares Jump +5%
Key Takeaways
- Novo Nordisk reported third-quarter 2026 adjusted net sales of DKK 79.2 billion, up 4% at constant exchange rates (CER), beating consensus estimates of roughly DKK 73.6 billion.
- Adjusted earnings per share (EPS) came in at DKK 5.79, down 12% year over year but above the Wall Street consensus of DKK 4.80.
- Obesity care sales rose 22% at constant exchange rates to DKK 26.15 billion, driven by strong GLP-1 volume growth, including the new Wegovy pill.
- Reported operating profit fell 9% at constant exchange rates to DKK 23.01 billion, weighed down by DKK 8.7 billion in non-cash impairment charges.
- The company raised its full-year 2026 outlook, now expecting adjusted sales and operating profit growth of -2% to +2% at constant exchange rates, up from a prior range of -6% to 0%.
- Shares climbed more than 5% in pre-market trading following the announcement.
Why These Results Matter Right Now
Novo Nordisk's third-quarter 2026 results arrived at a pivotal moment for the Danish pharmaceutical giant. After a turbulent stretch in which it ceded momentum to rival Eli Lilly in the fiercely competitive obesity and diabetes market, investors were watching closely for signs of a durable turnaround. The company's GLP-1 (glucagon-like peptide-1) franchise, anchored by Wegovy and Ozempic, remains central to its growth story, while the newly launched Wegovy pill represents its next major commercial test. With the stock having underperformed through much of 2025 and early 2026, this report served as a key gauge of whether improving patient volumes and pipeline momentum could restore confidence in the company's long-term trajectory. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Numbers
For the third quarter ended September 30, 2026, Novo Nordisk reported adjusted net sales of DKK 79.2 billion (Danish kroner), an increase of 6% in reported terms and 4% at constant exchange rates. That result exceeded the consensus estimate of approximately DKK 73.6 billion. Adjusted operating profit rose 27% at constant exchange rates to DKK 31.72 billion, also ahead of expectations.
Adjusted earnings per share came in at DKK 5.79, a 12% decline from the prior-year period but comfortably above the DKK 4.80 analysts had projected. Adjusted net profit totaled DKK 25.60 billion, down 12% year over year yet above the DKK 20.54 billion consensus.
On a reported basis, however, operating profit declined 9% at constant exchange rates to DKK 23.01 billion. The gap reflected DKK 8.7 billion in non-cash impairment charges, including a DKK 4.6 billion write-down tied to the investigational drug ziltivekimab and DKK 4.1 billion in charges related to restructuring of the company's manufacturing network.
Obesity care was the standout segment, with sales rising 22% at constant exchange rates to DKK 26.15 billion. The new Wegovy pill generated roughly DKK 5.4 billion in sales during the quarter. On the guidance front, Novo Nordisk raised its full-year 2026 outlook, now projecting adjusted sales and operating profit growth of -2% to +2% at constant exchange rates, an improvement from its previous -6% to 0% range, alongside expected free cash flow of DKK 60 billion to DKK 70 billion.
How the Market Reacted
The market responded favorably to the results, with NVO American depositary receipts climbing more than 5% in pre-market trading. Investors appeared to reward both the top- and bottom-line beats and, more importantly, the upward revision to full-year guidance, which signaled that management sees the business returning to a more stable footing. The strength of obesity care, particularly the rapid uptake of the Wegovy pill, helped ease concerns about the company's ability to compete in an increasingly crowded GLP-1 market. At the same time, the sizable impairment charges served as a reminder that the company's push to rationalize its manufacturing network and refocus its pipeline carries near-term costs, even as the underlying commercial performance improves.
What to Watch Going Forward
Looking ahead, investors will be tracking several themes as Novo Nordisk moves toward full-year 2026 and into 2027. The most closely watched catalyst is the planned U.S. launch of CagriSema, its next-generation obesity treatment, expected in early 2027 subject to regulatory approval. Success there could materially reshape the competitive landscape against Eli Lilly.
Pricing dynamics also warrant attention. The company has said it plans to cut the U.S. wholesale acquisition cost of Wegovy by about 50% and Ozempic by about 35%, bringing both to $675 beginning January 1, 2027. While these reductions aim to broaden patient access, they could pressure realized prices and revenue growth in the near term.
Finally, watch for continued execution on the Wegovy pill rollout across international markets, ongoing patient volume trends in both obesity and diabetes, and any further updates on manufacturing network restructuring costs. These factors will be central to determining whether the company's improved guidance can be sustained through the remainder of the year and beyond. From what I see, the volume trends in obesity care will be especially telling.
Using AI Tools in My Research
I often turn to Tickeron’s AI Screener when analyzing healthcare names like this one. It lets me quickly filter for technical patterns, fundamentals, and AI-driven signals across thousands of stocks, helping surface ideas that align with the themes I’m already tracking in the GLP-1 space. The tool has become a regular part of how I compare performance and spot potential setups without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NVO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for NVO turned positive on October 08, 2026. Looking at past instances where NVO's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on NVO as a result. In 52 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
NVO moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +3.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVO advanced for three days, in 203 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 163 of 255 cases where NVO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
NVO broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 19 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. NVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.842) is normal, around the industry mean (-1.235). P/E Ratio (1.605) is within average values for comparable stocks, (21.492). Projected Growth (PEG Ratio) (4.416) is also within normal values, averaging (5.738). Dividend Yield (0.044) settles around the average of (0.038) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement